Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Radiation Control Technologies Inc. Stories

2012-07-30 06:25:24

ROCKVILLE, Md., July 30, 2012 /PRNewswire/ -- Radiation Control Technologies, Inc. (RCTI), a private development stage biopharmaceutical company developing RCT1938, a novel radiosensitizer that sensitizes tumor cells to killing by radiation while protecting healthy cells from radiation damage by inhibiting the synthesis of the novel target protein CD47, announced today that it has been granted an exclusive license to two patents from the National Institutes of Health (NIH). The NIH exclusive...